Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lindane→

Lindane Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58-89-9
PubChem Substance Record
SID 483925796
Molecular formula
C6H6Cl6
Molecular weight
290.8 g/mol
Drug class
Organochlorine ectoparasiticideGABA-gated chloride-channel antagonist
Mechanism of action
Interferes with neuronal GABA-gated chloride channels in parasites, causing neuronal hyperstimulation and death of lice or mites. Human exposure can cause neurotoxicity; it is a second-line treatment only where still authorised.
Indications / reported uses
  • Historical or second-line treatment of scabies and pediculosis (lice) in selected jurisdictions when safer therapies have failed or are unsuitable; use is restricted because of neurotoxicity and should follow current local regulatory restrictions

Sources: US FDA — Lindane shampoo safety and restrictions · NLM MeSH — Lindane · FDA product information

Identification source: PubChem substance record (SID 483925796; no discrete CID). The linked PubChem record identifies lindane (gamma-hexachlorocyclohexane); it is distinct from technical-grade hexachlorocyclohexane mixtures.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lindane Environmental Risk Assessment (ERA) (the Lindane ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.